Volume XXXI, No. 2 – February 5, 2024
In this issue:
The Dark Report takes a deep dive into the comments submitted on the FDA’s draft LDT rule, questioning the FDA’s transparency in publishing the comments. Also included is a report on a letter about LDT oversight issued jointly by the FDA and CMS. In addition, a major data breach at a European lab has lessons for American clinical labs.